$FATE Cashflow Statement | Understand Stock

$FATE

$2.07 +$0.00 (0.0%) After hours

$FATE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization
Stock-based compensation
Accretion and amortization of premiums and discounts on investments, net
Amortization of collaboration contract asset
Deferred revenue
Changes in fair value of stock price appreciation milestones
Impairment of long-lived assets
Loss on disposal of property and equipment
Grant income from FT516 CIRM award
Changes in assets and liabilities:
Accounts receivable
Prepaid expenses and other assets
Accounts payable and accrued expenses
Right-of-use assets and lease liabilities, net
Net cash used in operating activities
Investing activities
Proceeds from sale of property and equipment
Purchases of property and equipment
Purchases of investments
Maturities of investments
Net cash provided by investing activities
Financing activities
Issuance of common stock from equity incentive plans, net of issuance costs
Proceeds from public offering of common stock, net of issuance costs
Proceeds from issuance of pre-funded warrants, net of issuance costs
Proceeds from private placement of common stock, net of issuance costs
Proceeds from sale of common stock to collaboration partner, net of issuance costs
Proceeds from FT819 CIRM award
Proceeds from FT836 CIRM award
Net cash provided by financing activities

Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of the year
Cash, cash equivalents and restricted cash at end of the year
Supplemental schedule of noncash investing and financing activities
Purchases of property and equipment in accounts payable
Right-of-use assets obtained in exchange for lease obligations
Accrued issuance costs included in additional paid-in-capital

Comments